CV Therapeutics Ranexa review
FDA's Cardiovascular & Renal Drugs Advisory Committee will review CV Therapeutics Ranexa (ranolazine) for treatment of chronic stable angina at its Dec. 9 meeting. Review of the partial fatty acid oxidation inhibitor was previously scheduled for mid-September but was cancelled because FDA and the company did not have enough time to prepare for the meeting. The meeting will take place at the Hilton in Gaithersburg, Md. beginning at 8 a.m. [To 1watch a webcast of the meeting, go to FDAAdvisoryCommittee.com]...
You may also be interested in...
October and November 2020 were bad months for companies seeking to have their planned EU filings fast-tracked through the centralized drug review system at the European Medicines Agency.
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.